China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with fellow Chinese firm Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Under the terms of the agreement, Livzon will obtain all rights to Synergy Pharma’s HHT120 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. In exchange, Livzon will pay Synergy Pharma RMB 86 million (USD 12 million) in patent and technology transfer fees, comprising upfront payment and milestone payments, as well as royalties on any future sales.
HHT120: A Thrombin Inhibitor for Venous Thromboembolism
HHT120, a thrombin inhibitor developed in-house by Synergy Pharmaceutical Sciences, received approval in China in April 2022 for the prevention of venous thromboembolism following major orthopedic surgeries. This licensing agreement positions Livzon to leverage the therapeutic potential of HHT120 in the Greater China region, expanding access to this critical medication for patients undergoing orthopedic procedures.
Expanding Access and Commercial Opportunities
The agreement not only strengthens Livzon’s product portfolio but also enhances its commercial opportunities in the region. With the rights to HHT120, Livzon is poised to improve patient outcomes and contribute to the healthcare landscape in Greater China, underscoring the company’s commitment to addressing unmet medical needs.-Fineline Info & Tech
